NASH is a worldwide epidemic disease affecting over 115 million people. Still, NASH remains an underdiagnosed and consequently an underreported disease. Untreated NASH may lead to cirrhosis, liver cancer and liver transplantation.
Our mission
The Swiss NASH Foundation is a non-for-profit organization committed to the dissemination of knowledge and raising of awareness about NASH. Through funding cutting edge research projects and increasing the knowledge and awareness about NASH, the foundation aims at contributing to treatment discovery as well as improving the patients’ quality of life.
Our history
In a joint effort to tackle the increasing prevalence and burden of NASH, scientific experts and the leading pharmaceutical companies: Gilead, Allergan, Genfit and Intercept have joined forces to establish The Swiss NASH Foundation.
Our vision
Prevent, diagnose and cure NASH.
Find out more
Swiss NASH Foundation: Mission and goals
News
- Beyond Diagnosis: Unlocking the Prognostic Power of FIB-4 in Patients with Obesity and Type 2 DiabetesAsk the author session with Prof. Quentin Anstee For healthcare professionals managing patients with metabolic dysfunction-associated steatotic liver disease (MASLD), obesity, and type 2 diabetes,… Read more: Beyond Diagnosis: Unlocking the Prognostic Power of FIB-4 in Patients with Obesity and Type 2 Diabetes
- Applying Noninvasive Screening for Advanced Fibrosis in MASLD: Insights from a Diabetology SettingAsk the author session with Prof. Caussy For specialists working in diabetology and related fields, identifying patients with metabolic dysfunction-associated steatotic liver disease (MASLD)-related advanced… Read more: Applying Noninvasive Screening for Advanced Fibrosis in MASLD: Insights from a Diabetology Setting
- Navigating the Challenges of MASLD and MASH Management in Europe: An Invitation to Watch Prof. Castera’s InsightsAsk the author session with Prof. Castera Are you a healthcare professional specializing in hepatology or related fields? Do you grapple with the increasing prevalence… Read more: Navigating the Challenges of MASLD and MASH Management in Europe: An Invitation to Watch Prof. Castera’s Insights
Living with NASH
Non-alcoholic steatohepatitis (NASH) is the consequence of abnormal fat accumulation in the liver leading to liver inflammation and damage. It is the most severe form of non-alcoholic liver disease (NAFLD), commonly called “fatty liver”. NASH is a worldwide epidemic disease affecting over 115 million people.
Still, NASH remains an under-diagnosed and consequently an underreported disease.
Many people live with NASH without knowing that they have a liver disease. The quality of life of these persons might be reduced due to their liver condition. Lifestyles can do a lot to improve NASH.
But changes in diet habits, regular physical activity are measures which can improve if not cure NASH.
